Characterization of weissella viridescens UCO-SMC3 as a potential probiotic for the skin: its beneficial role in the pathogenesis of acne vulgaris

Previously, we isolated lactic acid bacteria from the slime of the garden snail Helix aspersa Müller and selected Weissella viridescens UCO-SMC3 because of its ability to inhibit in vitro the growth of the skin-associated pathogen Cutibacterium acnes. The present study aimed to characterize the antimicrobial and immunomodulatory properties of W. viridescens UCO-SMC3 and to demonstrate its beneficial effect in the treatment of acne vulgaris. Our in vitro studies showed that the UCO-SMC3 strain resists adverse gastrointestinal conditions, inhibits the growth of clinical isolates of C. acnes, and reduces the adhesion of the pathogen to keratinocytes. Furthermore, in vivo studies in a mice model of C. acnes infection demonstrated that W. viridescens UCO-SMC3 beneficially modulates the immune response against the skin pathogen. Both the oral and topical administration of the UCO-SCM3 strain was capable of reducing the replication of C. acnes in skin lesions and beneficially modulating the inflammatory response. Of note, orally administered W. viridescens UCO-SMC3 induced more remarkable changes in the immune response to C. acnes than the topical treatment. However, the topical administration of W. viridescens UCO-SMC3 was more efficient than the oral treatment to reduce pathogen bacterial loads in the skin, and effects probably related to its ability to inhibit and antagonize the adhesion of C. acnes. Furthermore, a pilot study in acne volunteers demonstrated the capacity of a facial cream containing the UCO-SMC3 strain to reduce acne lesions. The results presented here encourage further mechanistic and clinical investigations to characterize W. viridescens UCO-SMC3 as a probiotic for acne vulgaris treatment.Fil: Espinoza-Monje, Marcela. Universidad de Concepción; ChileFil: Campos, Jorge. Universidad de Concepción; ChileFil: Alvarez Villamil, Eduardo Gaspar. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; ArgentinaFil: Jerez, Alonso. Universidad de Concepción; ChileFil: Dentice Maidana, Stefania. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; ArgentinaFil: Elean, Mariano Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; ArgentinaFil: Salva, Maria Susana. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; ArgentinaFil: Kitazawa, Haruki. Tohoku University; JapónFil: Villena, Julio Cesar. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; ArgentinaFil: García Cancino, Apolinaria. Universidad de Concepción; Chil

Postbiotic nasal priming improves of innate immune response in respiratory mucosa-associated lymphoid tissue in malnourished mice

The nasal priming of malnourished mice with the peptidoglycan (PG) of Lacticaseibacillus rhamnosus CRL1505 (Lr) is as effective as viable strain for improving systemic and respiratory immune response against Streptococcus pneumoniae (Sp). But the impact of these treatments on mucosa-associated lymphoid tissue is unknown. Hence, the effect of nasal administration of Lr or PG on the innate immune response of nasopharynx-associated lymphoid tissue (NALT) and cervical lymph nodes (CLN) in malnourished mice under repletion treatments was evaluated. Weaned Swiss mice were malnourished with a protein-free diet (PFD) for 21d. Malnourished mice received a balanced conventional diet (BCD) during 7d (BCD group) or BCD with nasal supplementation with Lr (108 cells/mouse/d) or PG (8 µg/mouse/d) during the last 2d of treatment (Lr or PG groups). Malnourished control mice (MNC) received PFD while the well-nourished control group (WNC) consumed BCD. On d8, all groups were infected with Sp (107 cells/mouse). Before infection, MNC showed a significant decrease of the total cells, T and B lymphocytes in NALT and CLN as well as the macrophages, myeloid and dendritic cells in NALT. In addition, the MNC showed an increase of NALT Gr-1+ cells % and the microbial load in nasal washes. BCD treatment was not able to normalize these parameters. However, the Lr and PG groups improved the total cells, B and T cells counts in NALT and CLN. Challenge with Sp increased the numbers of neutrophils and macrophages and TNF-α, INF-γ, IL-6, IL17 and IL-10 levels in nasal washes. The values were lower in MNC than in WNC. However, unlike the BDC group, Lr and PG groups showed values of NALT phagocytes, and lymphocytes, T CD4+ cells in CLN and NALT similar to WNC mice. Moreover, IL-6, INF-γ and TNF-α levels in nasal washes were higher in Lr or PG groups. NALT is a target for postbiotics administration to improve respiratory immunity in immunocompromised malnourished hosts.Fil: Ivir, Héctor Maximiliano. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; ArgentinaFil: Vasile, Brenda Estefania. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; ArgentinaFil: Gutiérrez, Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; ArgentinaFil: Alvarez Villamil, Eduardo Gaspar. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; ArgentinaFil: Lorenzo Pisarello, Maria Jose. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; ArgentinaFil: Salva, Maria Susana. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; ArgentinaFil: Alvarez, Susana. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; Argentina. Universidad Nacional de Tucumán. Facultad de Bioquímica, Química y Farmacia; ArgentinaLXVII Reunión anual de la Sociedad Argentina de Investigación Clínica; LXX Reunión Anual de la Sociedad Argentina de Inmunología; III Congreso Franco-Argentino de Inmunología; Reunión Anual 2022 Sociedad Argentina de FisiologíaMar del PlataArgentinaSociedad Argentina de Investigación ClínicaSociedad Argentina de InmunologíaSociedad Argentina de Fisiologí

International Nosocomial Infection Control Consortiu (INICC) report, data summary of 43 countries for 2007-2012. Device-associated module

We report the results of an International Nosocomial Infection Control Consortium (INICC) surveillance study from January 2007-December 2012 in 503 intensive care units (ICUs) in Latin America, Asia, Africa, and Europe. During the 6-year study using the Centers for Disease Control and Prevention's (CDC) U.S. National Healthcare Safety Network (NHSN) definitions for device-associated health care–associated infection (DA-HAI), we collected prospective data from 605,310 patients hospitalized in the INICC's ICUs for an aggregate of 3,338,396 days. Although device utilization in the INICC's ICUs was similar to that reported from ICUs in the U.S. in the CDC's NHSN, rates of device-associated nosocomial infection were higher in the ICUs of the INICC hospitals: the pooled rate of central line–associated bloodstream infection in the INICC's ICUs, 4.9 per 1,000 central line days, is nearly 5-fold higher than the 0.9 per 1,000 central line days reported from comparable U.S. ICUs. The overall rate of ventilator-associated pneumonia was also higher (16.8 vs 1.1 per 1,000 ventilator days) as was the rate of catheter-associated urinary tract infection (5.5 vs 1.3 per 1,000 catheter days). Frequencies of resistance of Pseudomonas isolates to amikacin (42.8% vs 10%) and imipenem (42.4% vs 26.1%) and Klebsiella pneumoniae isolates to ceftazidime (71.2% vs 28.8%) and imipenem (19.6% vs 12.8%) were also higher in the INICC's ICUs compared with the ICUs of the CDC's NHSN